FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in Relation to the Passing of GMP Compliance Inspection of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
20 March 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in relation to the Passing of GMP Compliance Inspection of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Fosun Aleph (Dalian) Biomedical Co., Ltd. * (復星雅立峰（大連）生物製藥有限公司) ("**Fosun Aleph**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the "**Company**" and, together with its subsidiaries/units, the "**Group**", the same applies below) recently received the "Notification of GMP Compliance Inspection of Medical Products" issued by Medical Products Administration of Liaoning Province, for which its workshop of undiluted rabies vaccine (undiluted vaccine production line) and second packaging workshop (vial preparation production line) located in located in the Dalian Economic and Technological Development Zone of Liaoning Province, have passed the Compliance Inspection for Good Manufacturing Practice of Medical Products (i.e. GMP Compliance Inspection, hereinafter refers as the "Inspection"), whereas the approval from the National Medical Products Administration (the "**NMPA**") for the registration application for marketing of Rabies Vaccine (Vero Cell) for Human Use (Freeze-dried) (the "**Vaccine**") which is independently developed by Fosun Aleph (the "**Approval**").

II. Registered information of the Vaccine

Generic name: Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried
Dosage form: Injection
Specification: After reconstitution, each bottle contains 0.5 ml. Each dose for human

use is 0.5 ml, and the potency of the rabies vaccine should not be less than 2.5 IU

Registered classification: Preventive biological products

Marketing authorization holder/producer: Fosun Aleph (Dalian) Biomedical Co., Ltd.*

Document No. of approval drug: GUOYAOZHUNZI S20240007

III. Research and market condition of the Vaccine

The Vaccine is prophylactic biological products developed independently by the Group, in lyophilized injection dosage form, for rabies prevention. In the preparation of Rabies Vaccine（Vero cell）for Human Use, Fosun Aleph adopted the serum-free medium production process at the virus culture stage. The CTN-1V strain used in the production of this vaccine has a gene sequence that is closer to that of the currently prevalent street strain of rabies virus, and has a better immune protection effect.

As of February 2024, the Group has invested approximately RMB167.67 million (unaudited) in total in the research and development("**R&D**") of the Vaccine at this stage

After enquiry on the website of the NMPA, as at the date of this announcement, save as the vaccine approved herein, 10 types of Rabies Vaccine (Vero Cell) for Human Use (Freeze-dried) have been approved for marketing in China (excluding Hong Kong, Macau and Taiwan for the purpose of this announcement), such as ones from Liaoning Chengda Bioengineering Co., Ltd. * (遼寧成大生物股份有限公司), Wuhan Institute of Biological Products Co., Ltd. * (武漢生物製品研究所有限責任公司) and Hualan Biological Vaccine Inc. * (華蘭生物疫苗股份有限公司).

IV. GMP Compliance Inspection

1. Conclusion of the Inspection

Name of enterprise: Fosun Aleph (Dalian) Biomedical Co., Ltd.*

Inspection location: 1 Tieshan Zhong Road, Dalian Economic and Technological Development Zone

Scope of inspection: Prophylactic biological products { Rabies Vaccine (Vero Cell) for Human Use (Freeze-dried) (vial) (small volume injection) [(Workshop of undiluted rabies

vaccine, production line of undiluted vaccine), (Second Packaging Workshop, production line of preparation of vial)].

Inspection conclusion: Compliance with the Good Manufacturing Practice of Medical Products.

2. Production facilities involved in this Inspection

The production facilities involved in this Inspection are Fosun Aleph existing undiluted rabies vaccine workshop (Undiluted Vaccine Production Line) and second packaging workshop (vial preparation production line). Among them, the details of the second packaging workshop (vial preparation production line), which passed the GMP Compliance Inspection for the first time, are as follows:

Name of the newly added production line	Designed capacity	Representative products
Second Packaging Workshop (vial preparation production line)	1.50 million person/ year	Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried

The Group's cumulative investment in response to this inspection amounted to approximately RMB46.06 million (unaudited).

V. The impact on the listed company and risk warning

Upon the passing of GMP Compliance Inspection, the relating production facilities of Fosun Aleph for Rabies Vaccine (Vero Cell) for Human Use (Freeze-dried) has compliance with the standards of Certification of Good Manufacturing Practice for Medical Products. Meanwhile, the approval for marketing of the Vaccine can brings more options to the prevention of rabies and further enrich the vaccine product line of the Group.

Due to the characteristic of prophylactic biological products, the specific sales performance after the market launch of such may be affected by factors including, but not limited to, the demand for vaccination, market competition, approval for release and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

20 March 2024